The antihistamines clemastine and desloratadine inhibit STAT3 and c-Myc activities and induce apoptosis in cutaneous T-cell lymphoma cell lines

Experimental Dermatology

Volumn 22, Issue 2, 2013, Pages 119-124

  Döbbeling, Udo ^a   Waeckerle Men, Ying ^a   Zabel, Franziska ^a   Graf, Nicole ^b   Kündig, Thomas M ^a   Johansen, Pål ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

C Myc; Cutaneous T cell lymphoma; Programmed death; STAT; Warburg effect

Indexed keywords

CD4 ANTIGEN; CLEMASTINE; DESLORATADINE; DNA; FEXOFENADINE; HYDROXYZINE; MYC PROTEIN; PROGRAMMED DEATH 1 LIGAND 1; STAT3 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL DEATH; CELL PROLIFERATION; DNA BINDING; HUMAN; LYMPHOCYTE; PROTEIN EXPRESSION; SEZARY SYNDROME;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CLEMASTINE; CYTOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTAMINE ANTAGONISTS; HUMANS; LORATADINE; LYMPHOMA, T-CELL, CUTANEOUS; PROTO-ONCOGENE PROTEINS C-MYC; STAT3 TRANSCRIPTION FACTOR;

EID: 84873170870     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/exd.12086     Document Type: Article

References (63)

1. Girardi M, Edelson R L. Oncology 2000: 14: 1061-1070.
2. Lutzner M, Edelson R, Schein P et al. Ann Intern Med 1975: 83: 534-552.
3. Olsen E, Vonderheid E, Pimpinelli N et al. Blood 2007: 110: 1713-1722.
4. Olsen E A, Whittaker S, Kim Y H et al. J Clin Oncol 2011: 29: 2598-2607.
5. Ralfkiaer E, O'Connor N T, Crick J et al. J Invest Dermatol 1987: 88: 762-765.
6. Agar N S, Wedgeworth E, Crichton S et al. J Clin Oncol 2010: 28: 4730-4739.
7. Vidulich K A, Talpur R, Bassett R L et al. Int J Dermatol 2009: 48: 243-252.
8. Dummer R, Heald P W, Nestle F O et al. Blood 1996: 88: 1383-1389.
9. Carter J, Zug K A. J Am Acad Dermatol 2009: 60: 39-50.
10. Willemze R, Dreyling M. Ann Oncol 2010: 21(Suppl. 5): v177-v180.
11. McGinnis K S, Shapiro M, Vittorio C C et al. Arch Dermatol 2003: 139: 771-775.
12. Kim E J, Hess S, Richardson S K et al. J Clin Invest 2005: 115: 798-812.
13. Scheinfeld N. J Drugs Dermatol 2007: 6: 757-760.
14. Qin J Z, Dummer R, Burg G et al. Blood 1999: 93: 260-267.
15. Sors A, Jean-Louis F, Pellet C et al. Blood 2006: 107: 2354-2363.
16. Weber-Nordt R M, Egen C, Wehinger J et al. Blood 1996: 88: 809-816.
17. Kiuchi N, Nakajima K, Ichiba M et al. J Exp Med 1999: 189: 63-73.
18. Anand P, Kunnumakkara A B, Harikumar K B et al. Cancer Res 2008: 68: 8861-8870.
19. Banerjee A, Grumont R, Gugasyan R et al. Blood 2008: 112: 5063-5073.
20. Nielsen M, Kaestel C G, Eriksen K W et al. Leukemia 1999: 13: 735-738.
21. Puthier D, Bataille R, Amiot M. Eur J Immunol 1999: 29: 3945-3950.
22. Silva M, Benito A, Sanz C et al. J Biol Chem 1999: 274: 22165-22169.
23. Qin J Z, Zhang C L, Kamarashev J et al. Blood 2001: 98: 2778-2783.
24. Vander Heiden M G, Cantley L C, Thompson C B. Science 2009: 324: 1029-1033.
25. Wise D R, DeBerardinis R J, Mancuso A et al. Proc Natl Acad Sci USA 2008: 105: 18782-18787.
26. Van Waardenburg R C, Prins J, Meijer C et al. Anticancer Res 1996: 16: 1963-1970.
27. Knapp D C, Mata J E, Reddy M T et al. Anticancer Drugs 2003: 14: 39-47.
28. Chen Y, Wu J J, Huang L. Mol Ther 2010: 18: 828-834.
29. Johansen P, Senti G. Clin Exp Allergy 2008: 38: 512-519.
30. Johansen P, Weiss A, Bünter A et al. J Allergy Clin Immunol 2011: 128: 1286-1294.
31. Primary cutaneous lymphomas. In: Edge S B, Byrd D R, Compton C C, Fritz A G, Greene F L, Trotti A, eds. AJCC Cancer Staging Manual. New York, NY: Springer, 2010: 613-615.
32. Safe S, Kim K. Prog Nucleic Acid Res Mol Biol 2004: 77: 1-36.
33. Follis A V, Hammoudeh D I, Wang H et al. Chem Biol 2008: 15: 1149-1155.
34. Huang M J, Cheng Y C, Liu C R et al. Exp Hematol 2006: 34: 1480-1489.
35. Salvatori B, Iosue I, Djodji Damas N, et al. Genes Cancer 2011: 2: 585-592.
36. Samini S, Benoit B M, Evans K et al. Arch Dermatol 2010: 146: 1388.
37. Cai G, Karni A, Oliveira E M et al. Cell Immunol 2004: 230: 89-98.
38. Freeman G J, Long A J, Iwai Y et al. J Exp Med 2000: 192: 1027-1034.
39. Latchman Y, Wood C R, Chernova T et al. Nat Immunol 2001: 2: 261-268.
40. Oltvai Z N, Milliman C L, Korsmeyer S J. Cell 1993: 74: 609-619.
41. Yang E, Zha J, Jockel J et al. Cell 1995: 80: 285-291.
42. Gough D J, Corlett A, Schlessinger K et al. Science 2009: 324: 1713-1716.
43. Wegrzyn J, Potla R, Chwae Y J et al. Science 2009: 323: 793-797.
44. Dang C V. Mol Cell Biol 1999: 19: 1-11.
45. Cancer Evan G. Science 2012: 335: 293-294.
46. Wise D R, Thompson C B. Trends Biochem Sci 2010: 35: 427-433.
47. Biaglow J E, Ayene I S, Koch C J et al. Biochem Biophys Res Commun 2000: 273: 846-852.
48. DeBerardinis R J, Mancuso A, Daikhin E et al. Proc Natl Acad Sci USA 2007: 104: 19345-19350.
49. Serkova N, Boros L G. Am J Pharmacogenomics 2005: 5: 293-302.
50. Nicklin P, Bergman P, Zhang B et al. Cell 2009: 136: 521-534.
51. Chang W K, Yang K D, Shaio M F. Clin Exp Immunol 1999: 117: 482-488.
52. Porro A, Haber M, Diolaiti D et al. J Biol Chem 2010: 285: 19532-19543.
53. Kanavaros P, Ioannidou D, Tzardi M et al. Pathol Res Pract 1994: 190: 767-774.
54. Meyer N, Paul C, Misery L. Acta Derm Venereol 2010: 90: 12-17.
55. Yamamoto T, Katayama I, Nishioka K. Blood 1997: 90: 1338-1340.
56. Brandes L J, LaBella F S, Warrington R C. J Natl Cancer Inst 1991: 83: 1329-1336.
57. Vermeer M H, Willemze R. J Am Acad Dermatol 1996: 35: 635-636.
58. Magro C M, Crowson A N. J Am Acad Dermatol 1995: 32: 419-428.
59. Akilov O E, Wu M X, Ustyugova I V Jr, Geskin L J et al. Exp Dermatol 2012: 21: 287-292.
60. Zhang C, Li B, Zhang X et al. J Invest Dermatol 2010: 130: 2110-2119.
61. Kacinski B M, Flick M. Ann N Y Acad Sci 2001: 941: 194-199.
62. Meech S J, Edelson R, Walsh P et al. Ann N Y Acad Sci 2001: 941: 46-58.
63. Guo J, Parise R A, Joseph E et al. Cancer Chemother Pharmacol 2009: 63: 615-625.